BioSpace News Archive

MDxHealth SA, a commercial-stage precision diagnostics company, announced it will release its financial results for the fourth quarter and full year ended December 31, 2022, after market close on Wednesday, March 8, 2023.

Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced it will file its fourth quarter and fiscal 2022 results on Wednesday, March 8, 2023 after market close and will host a conference call that same day at 4:30pm ET.

Impel Pharmaceuticals announced that it will implement an operational streamlining plan that will include a reduction of employee and non-employee expenses, largely impacting the research and development functions of the organization.

10x Genomics, Inc. announced the company will be participating in the upcoming 43rd Annual Cowen Healthcare Conference in Boston, Massachusetts.

Capstan Therapeutics, Inc. today announced that Capstan President and Chief Executive Officer, Laura Shawver, Ph.D., will participate in the upcoming Cowen 43rd Annual Health Care Conference, being held between March 6-8, 2023 at the Boston Marriott Copley Place in Boston, MA.

Jounce Therapeutics, Inc., a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced that it is reducing its workforce by approximately 57 percent.

Amicus Therapeutics (Nasdaq: FOLD) today announced positive results from the global Phase 3 open-label extension (OLE) study (ATB200-07) to investigate the long-term efficacy and safety of AT-GAA in adult patients with late-onset Pompe disease, an inherited lysosomal disorder caused by an enzyme deficiency that leads to the accumulation of glycogen in cells.

ICON plc, a world-leading healthcare intelligence and clinical research organization, reported its financial results for the fourth quarter and year ended December 31, 2022.

Lucira Health, Inc., a medical technology company, announced that it has filed for protection under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware.

Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented data suggesting that tesamorelin may improve metabolic profiles in people with HIV (PWHIV) by reducing excess visceral abdominal fat (EVAF).